Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaJohn C Byrd, Richard R Furman, Steven E Coutre, et al.Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.Pageof 4